首页> 外文期刊>Bone marrow transplantation >Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation.
【24h】

Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation.

机译:造血细胞移植治疗常染色体隐性遗传性高IgE综合征。

获取原文
获取原文并翻译 | 示例
       

摘要

Autosomal-recessive hyper-IgE syndrome (AR-HIES) is a combined immunodeficiency recently found to be associated with mutations of DOCK8. Clinically, this disorder is characterized beside recurrent bacterial complications, in particular by an unusual susceptibility to extensive cutaneous viral complications and by a high risk for squamous cell carcinoma. Here, we report on lasting control over the disorder in two patients by hematopoietic cell transplantation (HCT). Both patients were suffering from extensive long-lasting cutaneous viral complications, in particular from disfiguring molluscum contagiosum infections, when treated at the age of 10 and 17 years. Donors were matched unrelated, and conditioning was carried out with a combination of fludarabine, melphalan and BM-targeted radioimmunotherapy. Both patients developed stable, full donor cell chimerism, with the exception of persistent low-IgA serum levels and the exception of normal immune functions. Over the course of several months, cutaneous manifestations of viral disease resolved completely and both patients remain clinically well and free of infectious complications at 4 and 2 years, respectively, after transplantation. This represents the first report indicating HCT to be curative in patients with AR-HIES, which should be considered early before life-threatening complications develop, which include malignancies.
机译:常染色体隐性遗传超IgE综合征(AR-HIES)是最近发现的与DOCK8突变相关的综合免疫缺陷。在临床上,这种疾病的特征是除了反复出现细菌并发症外,特别是对广泛的皮肤病毒并发症有异常的敏感性,以及鳞状细胞癌的高风险。在这里,我们报告通过造血细胞移植(HCT)对两名患者的疾病的持久控制。两名患者在10岁和17岁接受治疗时均患有广泛的皮肤病毒长期持续并发症,特别是由于毁容性传染性软体动物感染。匹配的供体无关,并且通过氟达拉滨,美法仑和以BM为靶点的放射免疫治疗相结合进行调节。除了持续的低IgA血清水平和正常的免疫功能外,两名患者均发展出稳定的,完全的供体细胞嵌合体。在几个月的过程中,病毒性疾病的皮肤表现完全消失,并且在移植后的第4年和第2年,这两名患者的临床状况均保持良好,没有感染并发症。这代表了第一个表明HCT在AR-HIES患者中可以治愈的报告,应在威胁生命的并发症(包括恶性肿瘤)出现之前尽早考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号